Financials data is unavailable for this security.
View more
Year on year CanSino Biologics Inc 's revenues fell -65.49% from 1.03bn to 357.08m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 909.43m to a larger loss of 1.48bn.
Gross margin | 57.27% |
---|---|
Net profit margin | -144.25% |
Operating margin | -145.58% |
Return on assets | -10.15% |
---|---|
Return on equity | -15.80% |
Return on investment | -13.69% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at CanSino Biologics Inc fell by 1.35bn. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 908.23m for operations while cash used for investing totalled 449.65m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 20.45 |
---|---|
Tangible book value per share | 19.47 |
More ▼
Balance sheet in CNYView more
Current ratio | 2.41 |
---|---|
Quick ratio | 2.22 |
Total debt/total equity | 0.4339 |
---|---|
Total debt/total capital | 0.3026 |
More ▼